Skip to search formSkip to main contentSkip to account menu

elbasvir-grazoprevir drug combination

Known as: elbasvir grazoprevir drug combination, elbasvir, grazoprevir drug combination 
National Institutes of Health

Related topics

Related topics

6 relations

Broader (5)

Antiviral AgentsBenzofuransDrug CombinationsImidazoles

Narrower (1)

Zepatier

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2020
2020
Phase 3, Multicenter Open‐Label study to investigate the efficacy of elbasvir and grazoprevir fixed‐dose combination for 8 weeks in treatment‐naïve, HCV GT1b‐infected patients, with non‐severe…
Genotype 1b is the most common HCV genotype worldwide, accounting for the largest proportion of infections in Europe, Russia… 
2019
2019
The efficacy and safety of elbasvir/grazoprevir treatment in HCV genotype 1 patients in Taiwan
Elbasvir/grazoprevir (EBR/GZR) is a new generation, fixed‐dose, combination antiviral drug used in chronic hepatitis C virus (HCV… 
2019
2019
Real‐world experience with Grazoprevir/Elbasvir in the treatment of previously “difficult to treat” patients infected with hepatitis C virus genotype 1 and 4
Grazoprevir/elbasvir (GZR/EBR) was approved for the treatment of chronic hepatitis C virus (HCV) genotype 1 and 4 infected… 
2018
2018
Effectiveness and safety of elbasvir/grazoprevir therapy in patients with chronic HCV infection: Results from the Spanish HEPA‐C real‐world cohort
In randomized controlled trials of patients with chronic HCV infection, elbasvir/grazoprevir (EBR/GZR) demonstrated high cure… 
Review
2017
Review
2017
Elbasvir/grazoprevir for treatment of chronic hepatitis C virus infection
Hepatitis C is the leading cause of progressive liver fibrosis worldwide and results in cirrhosis, liver cancer, liver failure… 
Highly Cited
2016
Highly Cited
2016
Faculty Opinions recommendation of Grazoprevir-Elbasvir Combination Therapy for Treatment-Naive Cirrhotic and Noncirrhotic Patients With Chronic Hepatitis C Virus Genotype 1, 4, or 6 Infection: A…
2016
2016
C-EDGE IBLD: Efficacy and Safety of Elbasvir/Grazoprevir (EBR/GZR) in Subjects with Chronic Hepatitis C Virus Infection and Inherited Blood Disorders
Review
2016
Review
2016
Elbasvir and grazoprevir for chronic hepatitis C genotypes 1 and 4
ABSTRACT Introduction: During the last few years, treatment of hepatitis C virus (HCV) revolutionized with the appearance of… 
2016
2016
Safety and tolerability of elbasvir/grazoprevir in patients with chronic hepatitis C (HCV) infection: Integrated analysis of phase 2-3 trials
Review
2016
Review
2016
Safety and efficacy of elbasvir and grazoprevir for treatment of hepatitis C
ABSTRACT Introduction: The combination of elbasvir and grazoprevir in a single co-formulated tablet is highly effective for… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)